News Headlines
-
PharmaLogic Announces Opening Of Radiopharmaceutical Production Facility In New York City
5/13/2024
PharmaLogic Holdings Corp., ("PharmaLogic" or "the company"), a world-class contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, celebrates the opening of its radiopharmaceutical production and research facility in the Bronx, New York.
-
PHARMAP 2024 Highlights: From Cryogenic Storage To Patient-Centric Design
5/13/2024
PHARMAP 2024 brought together over 330 professionals from across the industry's value chain. Among attendees were contract manufacturing organisations, service providers and experts.
-
Ribobay Pharma Boosts CRDMO Offerings With Cytiva's First FlexFactory Platform For Oligonucleotides
5/10/2024
Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva's first FlexFactory platform for oligo manufacturing.
-
evitria And Lonza Sign License Agreement To Provide Fast Access To bYlok Bispecific Antibodies For Discovery-Stage Transient Expression Research
5/10/2024
evitria AG, a global antibody expression service provider located in Zurich, Switzerland, has entered into a non-exclusive bYlok bispecific pairing technology license agreement with Lonza.
-
ExcellGene SA And Cytovance Biologics Join Forces To Transform Large Molecule Biologics Development And Manufacture
5/8/2024
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA.
-
Siren Biotechnology And Catalent Enter Partnership For Manufacturing Of AAV Gene Therapies For Cancer
5/8/2024
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., the leader in enabling the development and supply of better treatments for patients worldwide, entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
-
MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
5/8/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors.
-
ARTBIO And Nucleus RadioPharma Announce Collaboration To Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 To Support Emerging Clinical Trials
5/7/2024
ARTBIO, Inc. (ARTBIO), a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), and Nucleus RadioPharma Inc. (Nucleus), the world’s first fully integrated development, manufacturing, and supply chain organization for radiopharmaceuticals, today announced a strategic manufacturing and supply agreement to support ARTBIO’s therapeutic product manufacturing.
-
Caring Cross And ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement To Commercialize TriCAR-T Cell Immunotherapy For Leukemia And Lymphoma
5/7/2024
Caring Cross, a 501(c)(3) non-profit dedicated to accelerating the development of advanced medicines and enabling access to cures for all patients, everywhere, and ImmunoAdoptive Cell Therapy (ImmunoACT), a Mumbai, India-based pioneering research and cell and gene therapy development company, announced an agreement to develop and commercialize a multi-targeted chimeric antigen receptor T-cell immunotherapy for leukemia and lymphoma.
-
Cellipont Bioservices And Adva Biotechnology Collaborate To Optimize Cell Therapy Manufacturing With The ADVA X3® Platform
5/7/2024
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.